GSDMD and melanoma: Consistently, analysis of a second dataset involving 68 advanced melanoma patients treated with nivolumab (23), either post-ipilimumab or ipilimumab-naïve, demonstrated that high GSDMD expression predicted inferior survival outcomes (HR = 1.8781, p = 0.014, Supplementary Figure 2).